What does Accuray do?

Accuray develops and sells precision radiation therapy systems and related software and services used by hospitals and cancer centres to treat tumours.

Why is Accuray considered risky?

As a small‑cap medical‑devices firm, Accuray faces product adoption cycles, regulatory requirements, competition from larger rivals and possible revenue volatility.

How does the company make money?

Revenues come from equipment sales, upgrades, service contracts and software—equipment sales tend to be lumpy while services can provide steadier recurring income.

Where can I check financials and updates?

Look at Accuray’s latest annual and quarterly reports, investor presentations and regulatory filings for revenue, cash flow and management commentary.

Is this a recommendation to buy?

No. This is general information only. Speak to a licensed adviser and consider your financial situation before investing.

Accuray (ARAY) Stock

Precision radiation therapy systems and services for hospitals. Here's the price, business snapshot, and what's worth knowing about Accuray in October 2026.

Accuray Incorporated (ARAY) designs and sells precision radiation therapy systems used to treat cancer, including the CyberKnife and Radixact platforms. The company supplies hardware, software and ongoing services to hospitals and cancer centres worldwide. With a modest market capitalisation of about $181.48M, Accuray is a small-cap medical‑devices business where revenue can be driven by equipment sales, upgrade cycles and recurring service or software contracts. Investors should note the typical industry dynamics: long capital outlays by customers, regulatory oversight, and competition from larger vendors. That combination can create periodic volatility in sales and margins. Accuray’s prospects hinge on product adoption, technological differentiation and stable service revenues, but there are execution and market‑share risks. This summary is educational only and not investment advice; individual suitability depends on your goals, timeframe and risk tolerance. Past performance is not a reliable indicator of future results and values can fall as well as rise.

≈

Why You’ll Want to Watch This Stock

📈

Adoption and upgrades

Equipment sales and upgrade cycles can drive revenue spikes, though buying decisions by hospitals are often lengthy and cyclical.

⚡

Technology edge

Differentiation via accuracy, software and workflow matters for market share, but competitors and regulatory hurdles can slow uptake.

🌍

Service revenues matter

Recurring service and software contracts can stabilise cash flow, yet overall performance will still vary and is not guaranteed.

Frequently asked questions

Accuray (ARAY) Stock

Precision radiation therapy systems and services for hospitals. Here's the price, business snapshot, and what's worth knowing about Accuray in October 2026.